Phaseline

Companies › RJK Biopharma

RJK Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RJK002
Intrathecal gene therapy
–Phase 1Amyotrophic Lateral Sclerosis AlsNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06493279RJK002Phase 1Amyotrophic Lateral Sclerosis AlsNeurologyNov 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.